{"id":"cc-93538","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_fixedAt":"2026-03-30T13:35:13.917835","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a next-generation cereblon ligand, CC-93538 binds cereblon and recruits Ikaros and Ikzf3 for proteasomal degradation, which enhances T-cell activation and proliferation while reducing immunosuppressive signaling. This mechanism differs from earlier IMiDs by providing more selective protein degradation with potentially improved tolerability. The drug is designed to enhance both innate and adaptive immune responses against cancer.","oneSentence":"CC-93538 is a cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Ikzf3 proteins to enhance T-cell proliferation and anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:01.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Lymphoma"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05214768","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis","status":"COMPLETED","sponsor":"Celgene","startDate":"2022-03-04","conditions":"Eosinophilic Gastroenteritis","enrollment":48},{"nctId":"NCT04991935","phase":"PHASE3","title":"Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2021-09-14","conditions":"Eosinophilic Esophagitis","enrollment":368},{"nctId":"NCT04753697","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-02-22","conditions":"Eosinophilic Esophagitis","enrollment":430},{"nctId":"NCT05175352","phase":"PHASE1","title":"A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab","status":"COMPLETED","sponsor":"Celgene","startDate":"2022-06-07","conditions":"Eosinophilic Esophagitis","enrollment":16},{"nctId":"NCT04800315","phase":"PHASE2","title":"A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-05-14","conditions":"Dermatitis, Atopic, Eczema","enrollment":221},{"nctId":"NCT05638282","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-15","conditions":"Healthy Participants","enrollment":25},{"nctId":"NCT05337345","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-05-02","conditions":"Healthy Volunteers","enrollment":104},{"nctId":"NCT04373187","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2020-06-22","conditions":"Healthy Volunteers","enrollment":52},{"nctId":"NCT04096105","phase":"PHASE1","title":"Japanese Pharmacokinetic Bridging Study for CC-93538","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-10-14","conditions":"Healthy Volunteers","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2025 Jul","pmid":"40374841","title":"Pharmacokinetic Characterization of Cendakimab Administered with Different Devices and at Different Injection Sites in Healthy Participants.","journal":"European journal of drug metabolism and pharmacokinetics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cendakimab","BMS-986355","RPC4064","cendakimab","RPC4046"],"phase":"phase_3","status":"active","brandName":"CC-93538","genericName":"CC-93538","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-93538 is a cereblon E3 ligase modulator (CELMoD) that degrades Ikaros and Ikzf3 proteins to enhance T-cell proliferation and anti-tumor immunity. Used for Multiple myeloma, Lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}